128833-96-5 Usage
General Description
2,6-Dichloro-DL-Phenylalanine is a chemical compound that consists of a phenylalanine molecule with two chlorine atoms attached at the 2 and 6 positions on the benzene ring. It is a white crystalline solid and is often used in the production of pharmaceuticals and agrochemicals. 2,6-Dichloro-DL-Phenylalanine has a wide range of applications, including as a building block in the synthesis of various drugs and as a key ingredient in the production of herbicides. It is also used in research and development processes for its potential therapeutic properties. Additionally, 2,6-Dichloro-DL-Phenylalanine is known for its ability to modify the structure of proteins, making it a valuable tool in biochemical studies.
Check Digit Verification of cas no
The CAS Registry Mumber 128833-96-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,8,8,3 and 3 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 128833-96:
(8*1)+(7*2)+(6*8)+(5*8)+(4*3)+(3*3)+(2*9)+(1*6)=155
155 % 10 = 5
So 128833-96-5 is a valid CAS Registry Number.
128833-96-5Relevant articles and documents
Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"
Varnavas, Antonio,Lassiani, Lucia,Valenta, Valentina,Mennuni, Laura,Makovec, Francesco,Hadjipavlou-Litina, Dimitra
, p. 563 - 581 (2007/10/03)
In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.
